Member Login


Tofacitinib for hospitalized acute severe Ulcerative colitis Management (the TRIUMPH study)


PIs: Dr. Neeraj Narula, McMaster University & Dr. Tawnya Hansen, University of Manitoba



Dr. Brian Bressler, University of British Columbia
Dr. Talat Bessissow, McGill University
Dr. Farhad Peerani, University of Alberta



The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in a subset of ulcerative colitis patients. We are looking to determine if there is benefit from tofacitinib in the severe hospitalized population.


Study Design

To determine the effectiveness (combined and endoscopic response) and safety of tofacitinib  in patients with acute severe UC who experience treatment failure to steroids or anti-TNFα/anti-integrin therapies/anti-interleukin therapies. The primary outcome of this study is to assess clinical response at day 7 among patients who receive tofacitinib.


Participating Sites

Hamilton Health Sciences Centre/McMaster University
University of Manitoba
McGill University
University of British Colombia
University of Alberta


For more information on Inclusion & Exclusion Criteriaclick here.



Anticipated sample size: 26
Anticipated start date: April 2021
Anticipated end: October 2022


Additional sites are welcome! Please contact Dr. Neeraj Narula at neeraj.narula@medportal.ca or Dr. Tawnya Hansen at hansen.tawnya@gmail.com for more information.